Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma
The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo. The late breaking results of the KEYNOTE-716 trial are presented ...
Sep 20, 2021
0
4